Literature DB >> 32409502

Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China.

Qingxian Cai1, Fengjuan Chen2, Tao Wang3, Fang Luo1, Xiaohui Liu1, Qikai Wu1, Qing He1, Zhaoqin Wang1, Yingxia Liu1, Lei Liu1, Jun Chen4, Lin Xu5.   

Abstract

OBJECTIVE: Patients with obesity are at increased risk of exacerbations from viral respiratory infections. However, the association of obesity with the severity of coronavirus disease 2019 (COVID-19) is unclear. We examined this association using data from the only referral hospital in Shenzhen, China. RESEARCH DESIGN AND METHODS: A total of 383 consecutively hospitalized patients with COVID-19 admitted from 11 January 2020 to 16 February 2020 and followed until 26 March 2020 at the Third People's Hospital of Shenzhen were included. Underweight was defined as a BMI <18.5 kg/m2, normal weight as 18.5-23.9 kg/m2, overweight as 24.0-27.9 kg/m2, and obesity as ≥28 kg/m2.
RESULTS: Of the 383 patients, 53.1% were normal weight, 4.2% were underweight, 32.0% were overweight, and 10.7% were obese at admission. Obese patients tended to have symptoms of cough (P = 0.03) and fever (P = 0.06) compared with patients who were not obese. Compared with normal weight patients, those who were overweight had 1.84-fold odds of developing severe COVID-19 (odds ratio [OR] 1.84, 95% CI 0.99-3.43, P = 0.05), while those who were obese were at 3.40-fold odds of developing severe disease (OR 3.40, 95% CI 1.40-2.86, P = 0.007), after adjusting for age, sex, epidemiological characteristics, days from disease onset to hospitalization, presence of hypertension, diabetes, cardiovascular disease, chronic obstructive pulmonary disease, liver disease, and cancer, and drug used for treatment. Additionally, after similar adjustment, men who were obese versus those who were normal weight were at increased odds of developing severe COVID-19 (OR 5.66, 95% CI 1.80-17.75, P = 0.003).
CONCLUSIONS: In this study, obese patients had increased odds of progressing to severe COVID-19. As the severe acute respiratory syndrome coronavirus 2 may continue to spread worldwide, clinicians should pay close attention to obese patients, who should be carefully managed with prompt and aggressive treatment.
© 2020 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2020        PMID: 32409502     DOI: 10.2337/dc20-0576

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  224 in total

1.  COVID-19 and Vulnerable Populations in Sub-Saharan Africa.

Authors:  J A George; M R Maphayi; T Pillay
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  [Obesity in the COVID era: A global health challenge].

Authors:  Miguel A Rubio Herrera; Irene Bretón Lesmes
Journal:  Endocrinol Diabetes Nutr       Date:  2020-10-21

3.  The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity.

Authors:  Hamid Bolouri; Cate Speake; David Skibinski; S Alice Long; Anne M Hocking; Daniel J Campbell; Jessica A Hamerman; Uma Malhotra; Jane H Buckner
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

Review 4.  Global pandemics interconnected - obesity, impaired metabolic health and COVID-19.

Authors:  Norbert Stefan; Andreas L Birkenfeld; Matthias B Schulze
Journal:  Nat Rev Endocrinol       Date:  2021-01-21       Impact factor: 43.330

5.  Interpreting, analysing and modelling COVID-19 mortality data.

Authors:  Didier Sornette; Euan Mearns; Michael Schatz; Ke Wu; Didier Darcet
Journal:  Nonlinear Dyn       Date:  2020-10-01       Impact factor: 5.022

Review 6.  Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications.

Authors:  Jun Ren; Ne N Wu; Shuyi Wang; James R Sowers; Yingmei Zhang
Journal:  Physiol Rev       Date:  2021-05-05       Impact factor: 37.312

7.  Impact of Body Mass Index on COVID-19-Related In-Hospital Outcomes and Mortality.

Authors:  Waqas Ullah; Sohaib Roomi; Nayab Nadeem; Rehan Saeed; Shafaq Tariq; Moataz Ellithi; Shujaul Haq; Ahmad Arslan; John Madara; Margot Boigon; Donald C Haas; David L Fischman
Journal:  J Clin Med Res       Date:  2021-04-27

Review 8.  Flavonoids are promising safe therapy against COVID-19.

Authors:  Moza Mohamed Alzaabi; Rania Hamdy; Naglaa S Ashmawy; Alshaimaa M Hamoda; Fatemah Alkhayat; Neda Naser Khademi; Sara Mahmoud Abo Al Joud; Ali A El-Keblawy; Sameh S M Soliman
Journal:  Phytochem Rev       Date:  2021-05-22       Impact factor: 7.741

9.  Neurological Manifestations and their Correlated Factors in COVID-19 Patients; a Cross-Sectional Study.

Authors:  Farzad Ashrafi; Davood Ommi; Alireza Zali; Sina Khani; Amirali Soheili; Mehran Arab-Ahmadi; Behdad Behnam; Shabnam Nohesara; Farbod Semnani; Alireza Fatemi; Mehri Salari; Reza Jalili Khoshnood; Mohammad Vahidi; Niloofar Ayoobi-Yazdi; Saeed Hosseini Toudeshki; Elham Sobhrakhshankhah
Journal:  Arch Acad Emerg Med       Date:  2021-04-27

Review 10.  Post-Acute COVID-19 Neurological Syndrome: A New Medical Challenge.

Authors:  Domenico Nuzzo; Sonya Vasto; Luca Scalisi; Salvatore Cottone; Gaetano Cambula; Manfredi Rizzo; Daniela Giacomazza; Pasquale Picone
Journal:  J Clin Med       Date:  2021-05-01       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.